Alzheimer's Brain Edema, Bleeding Rates Reported in Lecanemab Real-World Study

Algernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer’s Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology

VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has entered into share…

Alzheimer's Brain Edema, Bleeding Rates Reported in Lecanemab Real-World Study

(MedPage Today) -- Treating early Alzheimer's disease patients with lecanemab (Leqembi) was feasible and most patients tolerated the drug well, a retrospective study at one specialty memory clinic showed. Infusion-related reactions occurred in...

Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays

First-of-its-kind panel includes brain-derived pTau217, pTau181, pTau231, and total tau assays to advance neurodegenerative disease research FREMONT, Calif., May 15, 2025 /PRNewswire/ — Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the expansion of its NULISAseq™ CNS Disease Panel 120 to include novel assays for brain-derived phosphorylated tau (pTau) proteins. The enhanc…

Side Effects of New Alzheimer's Drug are 'Manageable' | Drug Discovery And Development

Adverse side effects of recently approved Alzheimer's therapy, lecanemab, are 'manageable', reported a new study published in JAMA Neurology. | Drug Discovery And Development

Annovis Bio Launches Phase 3 Alzheimer's Trial, Expands Research Efforts

Annovis Bio Inc. has advanced its Alzheimer’s disease research by launching a comprehensive Phase 3 clinical trial targeting early-stage patients. The trial, which began in the first quarter of 2025, will enroll up to 760 participants to evaluate the effectiveness of buntanetap over an 18-month period. The pharmaceutical company is investigating buntanetap’s potential to address both symptomatic manifestations and underlying disease progression …

A team of researchers has developed a vaccine targeting tau protein, associated with Alzheimer's disease, showing robust immune responses in mice and non-premium primates.